CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm. Th...
We received an updated WNV package insert; please note the manufacturer and license number has been ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In th...
On June 13, 2019, the new CTS Laboratory Information System was successfully implemented in Cha...